Buchumschlag

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	James Lok
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply
von: Chan Xie
Veröffentlicht: (2024)

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
von: Naohiro Yasuura, et al.
Veröffentlicht: (2024)

Editorial: HBV Integration: A Possible Key Driver in the Course of Patients With Chronic HBV Infection Under Viral Suppression
von: Hidenori Toyoda
Veröffentlicht: (2025)

Editorial: HBV Integration—A Possible Key Driver on the Course of Patients With Chronic HBV Infection Under Viral Suppression. Authors' Reply
von: Qin Ning, et al.
Veröffentlicht: (2025)

Editorial: Beyond DNA Suppression: HBV RNA as a Predictor of Hepatocarcinogenesis
von: Toshifumi Tada
Veröffentlicht: (2025)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
von: Jiong Yu, et al.
Veröffentlicht: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
von: Romeo Kuo‐Cheng Wu, et al.
Veröffentlicht: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
von: Terry Cheuk‐Fung Yip, et al.
Veröffentlicht: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
von: Stephanie Tsai, et al.
Veröffentlicht: (2025)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
von: Shuai Xia, et al.
Veröffentlicht: (2025)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC
von: Beom Kyung Kim
Veröffentlicht: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
von: Bingqiong Wang, et al.
Veröffentlicht: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
von: Stefan Mauss
Veröffentlicht: (2025)

Editorial: A Step Back to Leap Forward—Strategic Nucleos(t)ide Analogue Discontinuation Towards HBV Functional Cure
von: Xuwen Xu, et al.
Veröffentlicht: (2025)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC—Authors' Reply
von: Subin Heo, et al.
Veröffentlicht: (2025)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
von: Dong Hyun Kim, et al.
Veröffentlicht: (2025)

Letter: Using Anti‐ HBs Titres to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours
von: Tsutomu Nishida, et al.
Veröffentlicht: (2026)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
von: Sifu Yang
Veröffentlicht: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
von: Jialing Wang, et al.
Veröffentlicht: (2025)

Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply
von: Subin Heo, et al.
Veröffentlicht: (2025)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma—Authors' Reply
von: Jiwon Yang, et al.
Veröffentlicht: (2025)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
von: Yuanyan Sun, et al.
Veröffentlicht: (2026)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
von: Dong Hyun Kim, et al.
Veröffentlicht: (2025)

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC
von: Xiaosong Li, et al.
Veröffentlicht: (2024)

Letter: Antiviral Prophylaxis Mitigates HBV Reactivation Risk During Cancer Immunotherapy: Unresolved Challenges and Future Directions—Authors' Reply
von: Landon Long Chan, et al.
Veröffentlicht: (2025)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
von: Philip Vutien, et al.
Veröffentlicht: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
von: Yen‐Chun Liu, et al.
Veröffentlicht: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
von: Jeli Mendoza, et al.
Veröffentlicht: (2024)

Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’
von: James Turvill
Veröffentlicht: (2025)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
von: Konstantinos Arvanitakis, et al.
Veröffentlicht: (2024)

Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score
von: Ting Wang, et al.
Veröffentlicht: (2024)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
von: James L. Alexander, et al.
Veröffentlicht: (2024)

Review article: The epidemiology and management of Clostridioides difficile infection—A clinical update
von: Lindsay M. Clarke, et al.
Veröffentlicht: (2024)

Editorial: Understanding the Role of the Alpha‐1 Pi* MZ Genotype in the Development of Hepatocellular Carcinoma for Patients With ACLD
von: Kaitlyn Carlson, et al.
Veröffentlicht: (2026)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Editorial: Decoding Gut Failure in Cirrhosis—Villin‐1 and the Emergence of a Seventh Organ Failure. Authors' Reply
von: David Tornai, et al.
Veröffentlicht: (2026)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
von: Benedikt Silvester Hofer, et al.
Veröffentlicht: (2026)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
von: Christy Riggott, et al.
Veröffentlicht: (2024)

Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals
von: Mausam J. Patel, et al.
Veröffentlicht: (2024)